{"id":61238,"date":"2026-03-25T14:16:58","date_gmt":"2026-03-25T06:16:58","guid":{"rendered":"https:\/\/flcube.com\/?p=61238"},"modified":"2026-03-25T14:16:59","modified_gmt":"2026-03-25T06:16:59","slug":"henlius-biotech-wins-health-canada-approval-for-denosumab-biosimilars-bildyos-and-tuzemty-expand-organon-partnership-to-canada","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61238","title":{"rendered":"Henlius Biotech Wins Health Canada Approval for Denosumab Biosimilars \u2013 Bildyos and Tuzemty Expand Organon Partnership to Canada"},"content":{"rendered":"\n

Shanghai Henlius Biotech, Inc.<\/strong> (HKG: 2696<\/a>) announced marketing approval from Health Canada<\/strong> for Bildyos (denosumab 60 mg\/mL)<\/strong> and Tuzemty (denosumab 120 mg\/mL)<\/strong> \u2013 biosimilar versions of Amgen’s RANKL inhibitors Prolia\u00ae and Xgeva\u00ae<\/strong> \u2013 expanding the Organon partnership<\/strong> to Canada<\/strong> and advancing Henlius’s global biosimilar commercialization strategy<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>Health Canada<\/td><\/tr>
Products<\/strong><\/td>Bildyos (60 mg\/mL) + Tuzemty (120 mg\/mL)<\/td><\/tr>
Company<\/strong><\/td>Shanghai Henlius Biotech, Inc. (HKG: 2696)<\/td><\/tr>
Reference Products<\/strong><\/td>Prolia\u00ae + Xgeva\u00ae (denosumab, Amgen)<\/td><\/tr>
Mechanism<\/strong><\/td>RANKL inhibition<\/strong> \u2013 anti\u2011resorptive bone therapy<\/td><\/tr>
Commercial Partner<\/strong><\/td>Organon<\/strong> (NYSE: OGN) \u2013 exclusive rights outside China<\/td><\/tr>
Partnership Date<\/strong><\/td>2022 licensing deal<\/td><\/tr>
Canada Launch<\/strong><\/td>Expected 2026<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Approved Indications<\/h2>\n\n\n\n

Bildyos (60 mg\/mL) \u2013 Prolia\u00ae Biosimilar<\/h3>\n\n\n\n
Indication<\/th>Patient Population<\/th><\/tr><\/thead>
Postmenopausal osteoporosis<\/strong><\/td>High fracture risk<\/td><\/tr>
Male osteoporosis<\/strong><\/td>High fracture risk<\/td><\/tr>
Glucocorticoid\u2011induced osteoporosis<\/strong><\/td>Men and women, high fracture risk<\/td><\/tr>
Androgen deprivation therapy<\/strong><\/td>Men with nonmetastatic prostate cancer \u2013 bone mass increase<\/td><\/tr>
Aromatase inhibitor therapy<\/strong><\/td>Women with breast cancer \u2013 bone mass increase<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Tuzemty (120 mg\/mL) \u2013 Xgeva\u00ae Biosimilar<\/h3>\n\n\n\n
Indication<\/th>Patient Population<\/th><\/tr><\/thead>
Skeletal\u2011related events (SRE) prevention<\/strong><\/td>Multiple myeloma + solid tumor bone metastases<\/td><\/tr>
Giant cell tumor of bone<\/strong><\/td>Unresectable or surgery\u2011associated severe morbidity<\/td><\/tr>
Hypercalcemia of malignancy<\/strong><\/td>Refractory to bisphosphonate therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Partnership Structure \u2013 Henlius + Organon<\/h2>\n\n\n\n
Dimension<\/th>Henlius Responsibilities<\/th>Organon Responsibilities<\/th><\/tr><\/thead>
Development\/Manufacturing<\/strong><\/td>R&D, biologics production, quality control<\/td>\u2013<\/td><\/tr>
Commercialization<\/strong><\/td>\u2013<\/td>Exclusive rights outside China<\/strong> (US, Canada, EU, etc.)<\/td><\/tr>
Revenue Model<\/strong><\/td>Supply agreement + milestones\/royalties<\/td>In\u2011market sales, marketing, distribution<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Strategic Implications<\/h2>\n\n\n\n
Dimension<\/th>Denosumab Market<\/th>Henlius\/Organon Position<\/th><\/tr><\/thead>
Global Market Size<\/strong><\/td>US$4\u20115 billion<\/strong> annually (Prolia + Xgeva)<\/td>Biosimilar entry captures 20\u201130% share by 2030<\/td><\/tr>
Canada Market<\/strong><\/td>~US$300\u2011400 million denosumab market<\/td>First\u2011to\u2011market biosimilar advantage<\/strong>; automatic substitution potential<\/td><\/tr>
US Market Timing<\/strong><\/td>FDA approval anticipated 2026\u20112027<\/td>Organon US commercial infrastructure ready for launch<\/td><\/tr>
Competitive Landscape<\/strong><\/td>Samsung Bioepis, Sandoz, Pfizer developing denosumab biosimilars<\/td>Henlius\/Organon first\u2011mover<\/strong> in Canada; manufacturing quality differentiation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Outlook<\/h2>\n\n\n\n